{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:05:57Z","timestamp":1792119957331,"version":"4.4.0"},"reference-count":30,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["P30 AI036211"],"award-info":[{"award-number":["P30 AI036211"]}]},{"name":"NIH","award":["P30 CA125123"],"award-info":[{"award-number":["P30 CA125123"]}]},{"name":"NIH","award":["S10 RR024574"],"award-info":[{"award-number":["S10 RR024574"]}]},{"name":"NIH","award":["NCI-CA125123"],"award-info":[{"award-number":["NCI-CA125123"]}]},{"name":"NIH","award":["RP170691"],"award-info":[{"award-number":["RP170691"]}]},{"name":"NIH","award":["RP220646"],"award-info":[{"award-number":["RP220646"]}]},{"name":"AMS","award":["P30 AI036211"],"award-info":[{"award-number":["P30 AI036211"]}]},{"name":"AMS","award":["P30 CA125123"],"award-info":[{"award-number":["P30 CA125123"]}]},{"name":"AMS","award":["S10 RR024574"],"award-info":[{"award-number":["S10 RR024574"]}]},{"name":"AMS","award":["NCI-CA125123"],"award-info":[{"award-number":["NCI-CA125123"]}]},{"name":"AMS","award":["RP170691"],"award-info":[{"award-number":["RP170691"]}]},{"name":"AMS","award":["RP220646"],"award-info":[{"award-number":["RP220646"]}]},{"name":"Gilead Pharmaceuticals","award":["P30 AI036211"],"award-info":[{"award-number":["P30 AI036211"]}]},{"name":"Gilead Pharmaceuticals","award":["P30 CA125123"],"award-info":[{"award-number":["P30 CA125123"]}]},{"name":"Gilead Pharmaceuticals","award":["S10 RR024574"],"award-info":[{"award-number":["S10 RR024574"]}]},{"name":"Gilead Pharmaceuticals","award":["NCI-CA125123"],"award-info":[{"award-number":["NCI-CA125123"]}]},{"name":"Gilead Pharmaceuticals","award":["RP170691"],"award-info":[{"award-number":["RP170691"]}]},{"name":"Gilead Pharmaceuticals","award":["RP220646"],"award-info":[{"award-number":["RP220646"]}]},{"name":"Advanced Technology Cores","award":["P30 AI036211"],"award-info":[{"award-number":["P30 AI036211"]}]},{"name":"Advanced Technology Cores","award":["P30 CA125123"],"award-info":[{"award-number":["P30 CA125123"]}]},{"name":"Advanced Technology Cores","award":["S10 RR024574"],"award-info":[{"award-number":["S10 RR024574"]}]},{"name":"Advanced Technology Cores","award":["NCI-CA125123"],"award-info":[{"award-number":["NCI-CA125123"]}]},{"name":"Advanced Technology Cores","award":["RP170691"],"award-info":[{"award-number":["RP170691"]}]},{"name":"Advanced Technology Cores","award":["RP220646"],"award-info":[{"award-number":["RP220646"]}]},{"name":"Cancer Prevention and Research Institute of Texas","award":["P30 AI036211"],"award-info":[{"award-number":["P30 AI036211"]}]},{"name":"Cancer Prevention and Research Institute of Texas","award":["P30 CA125123"],"award-info":[{"award-number":["P30 CA125123"]}]},{"name":"Cancer Prevention and Research Institute of Texas","award":["S10 RR024574"],"award-info":[{"award-number":["S10 RR024574"]}]},{"name":"Cancer Prevention and Research Institute of Texas","award":["NCI-CA125123"],"award-info":[{"award-number":["NCI-CA125123"]}]},{"name":"Cancer Prevention and Research Institute of Texas","award":["RP170691"],"award-info":[{"award-number":["RP170691"]}]},{"name":"Cancer Prevention and Research Institute of Texas","award":["RP220646"],"award-info":[{"award-number":["RP220646"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Magrolimab (Magro) is a humanized naked anti-CD47 monoclonal antibody that blocks the SIRP\u03b1 CD47 interaction, allowing macrophages to target and destroy cancer cells. To evaluate its preclinical efficacy in vivo, Magro was tested as a single agent and in combination with conventional chemotherapy drugs, Cytarabine (Ara-C) or Azacitidine (Aza), in three pediatric AML (pAML) patient-derived xenograft (PDX) models\u2014AML006 (KMT2A::MLLT1), AML010 (+10, WT1), and AML013 (KMT2A::MLLT4). Methods: After PDX model establishment, mice were assigned to treatment groups hulgG4 (VC, vehicle control for Magro), Magro, Ara-C + VC, Aza + VC, Ara-C + Magro, and Aza + Magro, and then followed for survival. Mice that met humane euthanasia endpoints and at the culmination of experimental timelines had tissues harvested to measure disease burden. Results: Magro alone significantly improved survival in AML006 (p &lt; 0.0001) and AML013 (p = 0.003) and decreased bone marrow (BM) disease burden in AML006 (p = 0.009) and AML013 (p = 0.002). Ara-C + Magro therapy led to significantly improved survival in all three models and significantly decreased BM disease burden in AML006 (p &lt; 0.0001) and AML013 (p = 0.048). Aza + Magro therapy led to significantly improved survival in AML013 (p = 0.047) and AML010 (p = 0.017) and significantly lower BM disease burden in AML010 (p = 0.001). Conclusions: Interestingly, the two models that demonstrated improvement in survival with Magro harbored KMT2A rearrangements, suggesting a subset of patients that may be more responsive to the effects of CD47 blockade. As this drug is being evaluated for use in other malignancies, future studies may focus on investigating the importance of biomarker-based patient selection.<\/jats:p>","DOI":"10.3390\/cancers17091509","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T05:05:57Z","timestamp":1745989557000},"page":"1509","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Magrolimab Therapy in Conjunction with Conventional Chemotherapeutics Slows Disease Progression in Pediatric Acute Myeloid Leukemia Patient-Derived Xenograft Models"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1233-9741","authenticated-orcid":false,"given":"Julia G.","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Texas Children\u2019s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohani K.","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Texas Children\u2019s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritesh V.","family":"Dontula","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Texas Children\u2019s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh J.","family":"Cooper","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Texas Children\u2019s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaden","family":"Sherman","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Texas Children\u2019s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Rochette","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Texas Children\u2019s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehan","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Texas Children\u2019s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4084-1277","authenticated-orcid":false,"given":"Lana E.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Texas Children\u2019s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2515-3703","authenticated-orcid":false,"given":"Michelle S.","family":"Redell","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Texas Children\u2019s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7292-2464","authenticated-orcid":false,"given":"Alexandra M.","family":"Stevens","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Texas Children\u2019s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1200\/JCO.2015.62.8289","article-title":"Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia","volume":"33","author":"Zwaan","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-020-01009-3","article-title":"Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy","volume":"23","author":"Conneely","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e30584","DOI":"10.1002\/pbc.30584","article-title":"Children\u2019s Oncology Group\u2019s 2023 blueprint for research: Myeloid neoplasms","volume":"70","author":"Cooper","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Liu, J., Wang, L., Zhao, F., Tseng, S., Narayanan, C., Shura, L., Willingham, S., Howard, M., Prohaska, S., and Volkmer, J. (2015). Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0137345"},{"key":"ref_7","first-page":"1","article-title":"Role of CD47 in tumor immunity: A potential target for combination therapy","volume":"12","author":"Huang","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e17035","DOI":"10.1200\/JCO.2020.38.15_suppl.e17035","article-title":"Magrolimab and gemcitabine-cisplatin combination enhance phagocytic elimination of bladder cancer","volume":"38","author":"Kiss","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1182\/blood-2018-99-120170","article-title":"Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia","volume":"132","author":"Feng","year":"2018","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Rinaldi, C.R., Boasman, K., and Simmonds, M. (2023). Effects of ruxolitinib and magrolimab on calreticulin in myelofibrosis CD34+ cells in vitro: Proof of concept for combination therapy. J. Clin. Oncol., 41.","DOI":"10.1200\/JCO.2023.41.16_suppl.7064"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2019-126271","article-title":"The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results","volume":"134","author":"Asch","year":"2019","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2022-170188","article-title":"Phase I\/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older\/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed\/Refractory (R\/R) AML","volume":"140","author":"Daver","year":"2022","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin\u2019s Lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1182\/bloodadvances.2024013277","article-title":"Magrolimab plus rituximab in relapsed\/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1\/2 trial","volume":"8","author":"Mehta","year":"2024","journal-title":"Blood Adv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5864","DOI":"10.1182\/bloodadvances.2024013338","article-title":"Magrolimab plus rituximab with or without chemotherapy in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"8","author":"Maakaron","year":"2024","journal-title":"Blood Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2023-186997","article-title":"Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study","volume":"142","author":"Paul","year":"2023","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.ijrobp.2024.01.190","article-title":"Safety and Tolerability of Magrolimab Combination Therapy in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (RM-HNSCC)","volume":"118","author":"Colevas","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Fisher, G.A., Lakhani, N.J., Eng, C., Hecht, J.R., Bendell, J.C., Philip, P.A., O\u2019Dwyer, P.J., Johnson, B., Kardosh, A., and Ippolito, T.M. (2020). A phase Ib\/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients. J. Clin. Oncol., 38.","DOI":"10.1200\/JCO.2020.38.4_suppl.114"},{"key":"ref_20","first-page":"A792","article-title":"698 Safety and tolerability of magrolimab in combination with taxanes in patients with solid tumors","volume":"11","author":"Chiu","year":"2023","journal-title":"J. Immuno Therapy Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Subbiah, V., Vaishampayan, U.N., Puri, S., Lin, L., Chao, M., Ramsingh, G., Kummar, S., Strauss, J.F., and Patel, S.P. (2022). A phase 2, multiarm study of anti-CD47 antibody, magrolimab, in combination with docetaxel in patients with locally advanced or metastatic solid tumors. J. Clin. Oncol., 40.","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS584"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2021-145208","article-title":"A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53-Mutant Acute Myeloid Leukemia","volume":"138","author":"Daver","year":"2021","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1016\/S2152-2650(23)01083-2","article-title":"AML-577 A Phase III, Randomized Trial of Magrolimab in Combination with Venetoclax and Azacitidine in Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy (ENHANCE-3)","volume":"23","author":"Daver","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1158\/2159-8290.CD-NB2022-0012","article-title":"Safety Concerns Prompt Pause of Magrolimab Trials","volume":"12","author":"Dolgin","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1182\/blood-2023-187307","article-title":"Single-Cell Characterization of TP53-Mutated AML Patients Treated with Frontline Azacitidine, Venetoclax, and Magrolimab Reveals Mechanisms of Response and Resistance","volume":"142","author":"Desai","year":"2023","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Stevens, A.M., Terrell, M., Rashid, R., Fisher, K.E., Marcogliese, A.N., Gaikwad, A., Rao, P., Vrana, C., Krueger, M., and Loken, M. (2024). Addressing a Pre-Clinical Pipeline Gap: Development of the Pediatric Acute Myeloid Leukemia Patient-Derived Xenograft Program at Texas Children\u2019s Hospital at Baylor College of Medicine. Biomedicines, 12.","DOI":"10.3390\/biomedicines12020394"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1182\/blood-2024-203692","article-title":"Mutational Landscape and Depth of Response in Patients with Acute Myeloid Leukemia (AML) Treated with Magrolimab in Combination with Venetoclax and Azacitidine Compared to Placebo","volume":"144","author":"Johnson","year":"2024","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2022.280800","article-title":"Leukemic stem cells and therapy resistance in acute myeloid leukemia","volume":"108","author":"Stelmach","year":"2023","journal-title":"Haematologica"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S368","DOI":"10.1016\/S2152-2650(23)01193-X","article-title":"MDS-488 Magrolimab Alters the Tumor Microenvironment to Improve Bone Marrow Functions in Patients with Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS)","volume":"23","author":"Johnson","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/9\/1509\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:24:32Z","timestamp":1760030672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/9\/1509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["cancers17091509"],"URL":"https:\/\/doi.org\/10.3390\/cancers17091509","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]}}}